Skip to content

Risk Factors for Glaucoma in Musicians

Risk Factors for Glaucoma in Musicians

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01667861
Enrollment
40
Registered
2012-08-17
Start date
2011-10-31
Completion date
2015-01-31
Last updated
2015-05-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Glaucoma

Keywords

Glaucoma, Wind instruments

Brief summary

The purpose of this study is to determine the impact of playing wind instruments for the development of ocular hypertension and glaucoma, together with investigating the prevalence of visual problems and eye diseases in (professional) musicians.

Interventions

None listed

Sponsors

Stichting Glaucoomfonds
CollaboratorUNKNOWN
Henny Beckers
Lead SponsorOTHER

Study design

Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Healthy volunteers
Yes

Inclusion criteria

* All full time or part time professional players of participating symphony or wind orchestras, including guest players. * Retired players, if possible.

Exclusion criteria

* Difficulty in reading or speaking Dutch.

Design outcomes

Primary

MeasureTime frameDescription
IOP levels, including IOP peaks occurring during or directly after playing, and prevalence of glaucomatous field loss in players of wind instruments.One hour.
IOP peaks and variations during continuous IOP monitoring24 hoursSeveral high-risk participants will be asked their permission to perform continuous IOP monitoring during 24 hours with a sensing contact lens.

Secondary

MeasureTime frameDescription
Risk factors for glaucoma and the prevalence of visual problems and eye disease among (professional) musicians2 yearsParticipants of orchestras will be asked to fill in a questionnaire to collect demographic data together with data on musical history,ophthalmologic history and family history on glaucoma and ocular hypertension. From these participants, a selection will be invited for further screening.

Countries

Netherlands

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026